因为，不管是仿制药，toO4是研创新药，与欧美标1eLn接轨，同时，从药物的Us2K发阶段，申报阶段，到zibp产阶段，再到最后的上z6t5支付方式的一系列改革WF04都把门槛提得非常高，1e63多企业感觉到无所适从SbUr甚至很痛苦hWxu

Earningsinthechemicalsbusiness–whichcomprisestheChemicals,PerformanceProductsandFunctionalMaterialsSolutionssegments–weresignificantlyhigherthaninthepreviousyear.EBITbeforespecialitemsinthisbusinesswas€7.3billion,upby26%versustheprior-yearfigure.